Company news

Shanghai Medicilon, Inc. Class A (SSE:688202) news

Shanghai Medicilon, Inc. Class A news releases on 6ix. Latest, Sep 22, 2026: "Shanghai Medicilon Inc."Indicative Announcement on Change in Equity Interests…

Shanghai Medicilon, Inc. Class A (SSE:688202) news

Press releases & updates

"Shanghai Medicilon Inc."Indicative Announcement on Change in Equity Interests of Shareholder Reaching 1% Threshold

"Shanghai Medicilon Inc."Announcement on Progress of Litigation Involving the Subsidiary

"Shanghai Medicilon Inc."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026

"Shanghai Medicilon Inc."Announcement on Shareholding Reduction Plan of Shareholder

"Shanghai Medicilon Inc."Announcement on Use of Certain Temporarily Idle Raised Funds for Cash Management

"Shanghai Medicilon Inc."Indicative Announcement on Shareholders' Equity Change Reaching the 1% Threshold

Announcement on Subsidiary Filing a Counterclaim

Announcement on Release of Pledge of Shareholder's Shares

Announcement on Shareholding Reduction Plan for Shareholders

Announcement on Lifting Freeze of Partial Equity of Shareholder

Announcement on Election of Employee Representative Directors for the 4th Board of Directors

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Participating in the "Dialogue on Growth" 2025 Annual and Q1 2026 Performance Briefing

Report for Q1 2026

Announcement on Formulating and Revising Some Governance Systems

Announcement on Using Idle Self-owned Funds for Cash Management

Announcement on Release of Pledge of Partial Equity of Shareholder

Announcement on Preliminary Earnings Estimate for 2025

SHANGHAI MEDICILON INC.: Earnings Preannouncement for 2025

Announcement on Early Termination of Shareholding Reduction Plan for Shareholders and Results of Shareholding Reduction

Announcement on Adjustment of Investment Types for Cash Management Using Idle Own Funds

Announcement on Shareholding Reduction Plan for Shareholder

Announcement on Expiration of Plan by Shareholder and Results of Shareholding Reduction

Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025

Announcement on the Completion of Non-Trade Stock Transfer under the 2025 Employee Stock Ownership Plan

Announcement on Resolutions of the 1st Holders' Meeting for 2025 Employee Stock Ownership Plan

Self-Inspection Report on the Trading of the Company's Stocks by Information Insiders of 2025 Restricted Stock Incentive Plan

Publicity Explanation and Verification Opinions of the Remuneration and Appraisal Committee of the Board of Directors on List of Initially Granted Incentive Objects in the 2025 Restricted Stock Incentive Plan

Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025

Announcement on Litigation Involving Subsidiary

Special Report on Semi-annual Deposit, Management and Actual Use of Raised Funds in 2025

Announcement on Resolutions of the 5th Meeting of the 4th Board of Supervisors

Announcement on Implementation Results of Share Repurchase and Share Changes

Announcement on Abnormal Fluctuations in Stock Trading

Announcement on Progress in Repurchasing Shares through Call Auction

Announcement on Equity Change of Shareholders Reaching 1% and Results of Shareholding Reduction

Medicilon Passes FDA Inspection, Reinforcing Global R&D Excellence

Announcement on Repurchasing 1% Shares through Call Auction and Progress in Repurchasing Shares

Announcement on Resolution of the 2024 Annual General Meeting

Announcement on Share Reduction Plan for Shareholder

Announcement on Attending the Annual Collective Performance Briefing for Innovative Drug Industry on SSE STAR Market 2024 and Convening Q1 2025 Performance Briefing

Announcement on Initially Repurchasing the Company's Shares through Call Auction

Announcement on Provision for Asset Impairment and Write-off of Assets in 2024

Announcement on the Progress of Half Repurchase Period

Announcement on Preliminary Earnings Estimate for 2024

Announcement on Postponing Some Investment Projects Financed by Raised Funds

Annual Earnings Preannouncement for 2024

Announcement on Electing Chairman, Chairman of the Board of Supervisors, and Members of Special Committees of the Board of Directors, and Appointing Senior Management Members and Securities Affairs Representative

Announcement on Shareholdings of Top 10 Shareholders and Top 10 Holders of Shares Without Sales Restrictions Concerning Share Repurchase